| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Biomm S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | R$8.90 |
| 52 Week High | R$21.20 |
| 52 Week Low | R$4.15 |
| Beta | 0.86 |
| 11 Month Change | -11.88% |
| 3 Month Change | -24.70% |
| 1 Year Change | 109.41% |
| 33 Year Change | -32.73% |
| 5 Year Change | 2.53% |
| Change since IPO | 1,171.43% |
Recent News & Updates
Biomm S.A. (BVMF:BIOM3) Investors Are Less Pessimistic Than Expected
Jul 05
Is Biomm (BVMF:BIOM3) Weighed On By Its Debt Load?
May 24Biomm S.A.'s (BVMF:BIOM3) 69% Price Boost Is Out Of Tune With Revenues
Apr 18Recent updates
Biomm S.A. (BVMF:BIOM3) Investors Are Less Pessimistic Than Expected
Jul 05Is Biomm (BVMF:BIOM3) Weighed On By Its Debt Load?
May 24Biomm S.A.'s (BVMF:BIOM3) 69% Price Boost Is Out Of Tune With Revenues
Apr 18Biomm S.A.'s (BVMF:BIOM3) Share Price Is Matching Sentiment Around Its Revenues
Feb 21Biomm (BVMF:BIOM3) Is Making Moderate Use Of Debt
Nov 12We Think Biomm (BVMF:BIOM3) Has A Fair Chunk Of Debt
Jul 25Positive Sentiment Still Eludes Biomm S.A. (BVMF:BIOM3) Following 26% Share Price Slump
Apr 17Biomm (BVMF:BIOM3) Is Making Moderate Use Of Debt
Feb 28Biomm (BVMF:BIOM3) Is Making Moderate Use Of Debt
Oct 15Biomm (BVMF:BIOM3) Is Carrying A Fair Bit Of Debt
Jun 29We Think Biomm (BVMF:BIOM3) Has A Fair Chunk Of Debt
Aug 17Here's Why Biomm (BVMF:BIOM3) Can Afford Some Debt
Apr 05Biomm (BVMF:BIOM3) Shareholders Have Enjoyed An Impressive 173% Share Price Gain
Mar 01Do Institutions Own Biomm S.A. (BVMF:BIOM3) Shares?
Jan 25Is Biomm (BVMF:BIOM3) A Risky Investment?
Dec 21Shareholder Returns
| BIOM3 | BR Biotechs | BR Market | |
|---|---|---|---|
| 7D | 0% | 0.9% | 0.7% |
| 1Y | 109.4% | 21.6% | 9.6% |
Return vs Industry: BIOM3 exceeded the BR Biotechs industry which returned 21.6% over the past year.
Return vs Market: BIOM3 exceeded the BR Market which returned 9.6% over the past year.
Price Volatility
| BIOM3 volatility | |
|---|---|
| BIOM3 Average Weekly Movement | 9.4% |
| Biotechs Industry Average Movement | 9.2% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in BR Market | 9.1% |
| 10% least volatile stocks in BR Market | 2.2% |
Stable Share Price: BIOM3's share price has been volatile over the past 3 months compared to the BR market.
Volatility Over Time: BIOM3's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of BR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 130 | Heraldo Marchezini | www.biomm.com |
Biomm S.A. operates as a biotechnology company in Brazil. The company offers AFREZZA, a human insulin inhalation powder; GHEMAXAN, an enoxaparina sodica; GLARGILIN, a glargine insulin; WOSULIN R, a human insulin; WOSULIN N, an isophane insulin; HERZUMA, a trastuzumab; and CANETA LIFEPEN G PARA APLICACAO DE INSULINA. Biomm S.A. was founded in 2001 and is headquartered in Nova Lima, Brazil.
Biomm S.A. Fundamentals Summary
| BIOM3 fundamental statistics | |
|---|---|
| Market cap | R$1.13b |
| Earnings (TTM) | -R$78.35m |
| Revenue (TTM) | R$123.78m |
9.1x
P/S Ratio-14.4x
P/E RatioIs BIOM3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOM3 income statement (TTM) | |
|---|---|
| Revenue | R$123.78m |
| Cost of Revenue | R$95.84m |
| Gross Profit | R$27.94m |
| Other Expenses | R$106.29m |
| Earnings | -R$78.35m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 13, 2024
| Earnings per share (EPS) | -0.62 |
| Gross Margin | 22.57% |
| Net Profit Margin | -63.30% |
| Debt/Equity Ratio | 43.7% |
How did BIOM3 perform over the long term?
See historical performance and comparison